The latest drug approval announced by the FDA is a reminder that it's possible that the decision on trofinetide could come any day now.
The FDA has approved Chiesi Global Rare Diseases’ velmanase alfa (Lamzede), an enzyme replacement therapy for the treatment of alpha-mannosidosis.
Chiesi received notice of acceptance of its BLA and granting of priority review on 12 September, 2022, the same day on which Acadia received acceptance of its NDA and granting of priority review.
https://www.fda.gov/drugs/new-drugs...biological-products/novel-drug-approvals-2023
https://chiesirarediseases.com/media/pr-on-lamzede-9_12_22
Share Price, page-3762
-
- There are more pages in this discussion • 6,955 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.00 |
Change
0.090(0.45%) |
Mkt cap ! $2.556B | |||
| Open | High | Low | Value | Volume |
| $19.88 | $20.07 | $19.73 | $11.80M | 591.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5901 | $19.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.00 | 3262 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |